Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07592000 · ClinicalTrials.gov registry record · Phase 1
Breakthrough - T1DM and Chronic Kidney Disease
A Phase 1 study, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT07592000: Recruiting Phase 1 study, sponsored by University of Chicago.
NCT07592000 is a Phase 1 study that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07592000, a Phase 1 study, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Single arm- subject treated with Tegoprubart and everolimus. The purpose of this research is to gather information on the safety and effectiveness of investigational regimen containing 2 experimental components: * An investigational drug called Tegoprubart and * Human pancreatic islet cells Both Tegoprubart and human pancreatic islet cells are considered investigational because they are not approved for use in the United States by the Food and Drug Administration (FDA). Participation in this research will last about 5 years. Assess safety, tolerability, and efficacy of transplanted islet cells and immunomodulation with Tegoprubart in combination with anti-thymocyte globulin (ATG), etanercept and with everolimus in adults with brittle T1D and chronic kidney disease (stage 2-3a).
Primary Outcome
Assessed by continuous glucose monitoring (CGM) for insulin independence, HbA1c\<7.0 (53 mmol/mol), and no severe hypoglycemic episodes (SHE).
Interventions
- BIOLOGICAL Islet Cell Transplant
- DRUG Tegoprubart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2027-04-29 |
| Est. Completion | 2030-01-31 |
| Phase | Phase 1 |
What NCT07592000 shows while recruiting
NCT07592000 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 2 interventions - of which Islet Cell Transplant is the first listed.
NCT07592000 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07592000 about?
NCT07592000 is a clinical study titled "Breakthrough - T1DM and Chronic Kidney Disease". Single arm- subject treated with Tegoprubart and everolimus. The purpose of this research is to gather information on the safety and effectiveness of investigational regimen containing 2 experimental components: * An investigational drug called Tegoprubart and * Human pancreatic islet cells Both ...
What is the current status of trial NCT07592000?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2027-04-29. Estimated completion is 2030-01-31.
What interventions are being tested in trial NCT07592000?
The interventions under investigation include: Islet Cell Transplant (BIOLOGICAL), Tegoprubart (DRUG).
Who is sponsoring clinical trial NCT07592000?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07592000's enrollment target sits among peer trials
10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI